Biomarkers of atherosclerosis: Clinical applications

被引：30

作者：

Brown T.M. ^{[1
]}

Bittner V. ^{[1
]}

机构：

[1] Department of Preventive Cardiology, University of Alabama at Birmingham, Division of Cardiovascular Disease, Birmingham, AL 35294-0007

来源：

Current Cardiology Reports | 2008年 / 10卷 / 6期

基金：

美国医疗保健研究与质量局;

关键词：

Coronary Artery Calcium; Brain Natriuretic Peptide; Rosuvastatin; Coronary Artery Calcium Score; Traditional Risk Factor;

D O I：

10.1007/s11886-008-0078-1

中图分类号：

学科分类号：

摘要：

Current cardiovascular risk prediction models incorporate traditional risk factors to estimate 10-year cardiovascular risk. Numerous blood-based biomarkers have been identified that are associated with increased cardiovascular risk after adjusting for traditional risk factors. Many of these biomarkers, alone or in combination, have been incorporated into risk prediction models to determine whether their addition increases the model's predictive ability. We review the recently published literature on blood-based biomarkers and examine whether incorporating these markers may improve clinical decision making. © Current Medicine Group LLC 2008.

引用

页码：497 / 504

页数：7

共 50 条

[1]

Wilson P.W., D'Agostino R.B., Levy D., Et al., Prediction of coronary heart disease using risk factor categories, Circulation, 97, pp. 1837-1847, (1998)

[2]

Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)

[3]

Lloyd-Jones D.M., Leip E.P., Larson M.G., Et al., Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age, Circulation, 113, pp. 791-798, (2006)

[4]

Ware J.H., The limitations of risk factors as prognostic tools, N Engl J Med, 355, pp. 2615-2617, (2006)

[5]

Cook N.R., Use and misuse of the receiver operator characteristic curve in risk prediction, Circulation, 115, pp. 928-935, (2007)

[6]

Brunzell J.D., Davidson M., Furberg C.D., Et al., Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol, 51, pp. 1512-1524, (2008)

[7]

Sacks F.M., The apolipoprotein story, Atheroscler Suppl, 7, pp. 23-727, (2006)

[8]

Barter P.J., Ballantyne C.M., Carmena R., Et al., Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty person/ten country panel, J Intern Med, 259, pp. 247-258, (2006)

[9]

Frontini M.G., Srinivasan S.R., Xu J., Et al., Usefulness of childhood non high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study, Pediatrics, 121, pp. 924-929, (2008)

[10]

Ingelsson E., Schaefer E.J., Contois J.H., Et al., Clinical utility of different lipid measures for prediction of coronary heart disease in men and women, JAMA, 298, pp. 776-785, (2007)

← 1 2 3 4 5 →